NIH Grants for Cureveda's Systemic Sclerosis and COPD Studies

Author: Curevedas
Date Published: January-2015
Source: Advance Healthcare Network

The National Institutes of Health (NIH) recently granted two $450,000 Phase I Small Business Technology Transfer (STTR) grants to Cureveda LLC, who is currently developing new therapies for the treatment of inflammatory and fibrotic diseases, such as scleroderma. The company will invest the grants in its ongoing preclinical studies that are going to evaluate its lead investigational product VEDA-1209 to treat systemic sclerosis and chronic obstructive pulmonary disease (COPD).